Strides Arcolab gets USFDA nod for injectable Acetazolamide

NEW DELHI: Drug firm Strides Arcolab today said it has received US health regulator's approval to sell injectable Acetazolamide in the American market.

The company has received approval from the US Food and Drug Administration for 'Acetazolamide for Injection USP, 500 mg/ vial (preservative free) in lyophilized format', Strides Arcolab said in a statement.

According to IMS data, the 2011 US market for injectable Acetazolamide stood at about USD 10 million with only one active player.

"The product is expected to be launched shortly," the company said. Acetazolamide is the fourteenth product approved under the Sagent-Strides partnership.

Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

Acetazolamide is used for treating various diseases, including edema due to congestive heart failure and secondary glaucoma.

Shares of Strides Arcolab today closed at Rs 691.55 on the BSE, up 0.24 per cent from its previous close.